|
1
|
Richter A, Fichtner A, Joost J, Brockmeyer P, Kauffmann P, Schliephake H, Hammerstein-Equord A, Kueffer S, Urlaub H, Oellerich T, Ströbel P, Bohnenberger H, Bremmer F. Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry. JOURNAL OF PATHOLOGY CLINICAL RESEARCH 2021; 8:33-47. [PMID: 34647699 PMCID: PMC8682946 DOI: 10.1002/cjp2.244] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Revised: 07/23/2021] [Accepted: 09/01/2021] [Indexed: 12/16/2022]
Abstract
The differentiation between a pulmonary metastasis and a newly developed squamous cell carcinoma of the lung in patients with prior head and neck squamous cell carcinoma (HNSCC) is difficult due to a lack of biomarkers but is crucially important for the prognosis and therapy of the affected patient. By using high‐resolution mass spectrometry in combination with stable isotope labelling by amino acids in cell culture, we identified 379 proteins that are differentially expressed in squamous cell carcinomas of the lung and the head and neck. Of those, CAV1, CAV2, LGALS1, LGALS7, CK19, and UGDH were tested by immunohistochemistry on 194 tissue samples (98 lung and 96 HNSCCs). The combination of CAV1 and LGALS7 was able to distinguish the origin of the squamous cell carcinoma with high accuracy (area under the curve 0.876). This biomarker panel was tested on a cohort of 12 clinically classified lung tumours of unknown origin after HNSCC. Nine of those tumours were immunohistochemically classifiable.
Collapse
Affiliation(s)
- Annika Richter
- Institute of Pathology, University Medical Centre Göttingen, Göttingen, Germany
| | - Alexander Fichtner
- Institute of Pathology, University Medical Centre Göttingen, Göttingen, Germany
| | - Jasmin Joost
- Institute of Pathology, University Medical Centre Göttingen, Göttingen, Germany
| | - Philipp Brockmeyer
- Department of Oral and Maxillofacial Surgery, University Medical Centre Göttingen, Göttingen, Germany
| | - Philipp Kauffmann
- Department of Oral and Maxillofacial Surgery, University Medical Centre Göttingen, Göttingen, Germany
| | - Henning Schliephake
- Department of Oral and Maxillofacial Surgery, University Medical Centre Göttingen, Göttingen, Germany
| | | | - Stefan Kueffer
- Institute of Pathology, University Medical Centre Göttingen, Göttingen, Germany
| | - Henning Urlaub
- Bioanalytical Mass Spectrometry Group, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany.,Bioanalytics, Institute for Clinical Chemistry, University Medical Centre Göttingen, Göttingen, Germany
| | - Thomas Oellerich
- Department of Medicine II, Haematology/Oncology, Goethe University, Frankfurt, Germany.,German Cancer Research Centre and German Cancer Consortium, Heidelberg, Germany
| | - Philipp Ströbel
- Institute of Pathology, University Medical Centre Göttingen, Göttingen, Germany
| | | | - Felix Bremmer
- Institute of Pathology, University Medical Centre Göttingen, Göttingen, Germany
| |
Collapse
|
|
2
|
Abstract
Resistance of solid tumors to chemo- and radiotherapy remains a major obstacle in anti-cancer treatment. Herein, the membrane protein caveolin-1 (CAV1) came into focus as it is highly expressed in many tumors and high CAV1 levels were correlated with tumor progression, invasion and metastasis, and thus a worse clinical outcome. Increasing evidence further indicates that the heterogeneous tumor microenvironment, also known as the tumor stroma, contributes to therapy resistance resulting in poor clinical outcome. Again, CAV1 seems to play an important role in modulating tumor host interactions by promoting tumor growth, metastasis, therapy resistance and cell survival. However, the mechanisms driving stroma-mediated tumor growth and radiation resistance remain to be clarified. Understanding these interactions and thus, targeting CAV1 may offer a novel strategy for preventing cancer therapy resistance and improving clinical outcomes. In this review, we will summarize the resistance-promoting effects of CAV1 in tumors, and emphasize its role in the tumor-stroma communication as well as the resulting malignant phenotype of epithelial tumors.
Collapse
Affiliation(s)
- Julia Ketteler
- Institute for Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Diana Klein
- Institute for Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| |
Collapse
|
|
3
|
Machado I, Yoshida A, López-Guerrero JA, Nieto MG, Navarro S, Picci P, Llombart-Bosch A. Immunohistochemical analysis of NKX2.2, ETV4, and BCOR in a large series of genetically confirmed Ewing sarcoma family of tumors. Pathol Res Pract 2017; 213:1048-1053. [DOI: 10.1016/j.prp.2017.08.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2017] [Revised: 08/15/2017] [Accepted: 08/15/2017] [Indexed: 12/25/2022]
|